AbbVie Inc. · ABBV · FY2025 Q3 · Calendar Q4 2025
AbbVie: Immunology growth offsets biosimilar and pricing risks
The latest analysis supports a constructive but qualified view: resilient immunology and neuroscience growth, raised guidance and pipeline progress strengthen the growth case, while biosimilar erosion, pricing changes and aesthetics softness remain material counterweights.
Research this report with FN2. Free to start; review your question before sending.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about ABBV FY2025 Q3
Choose a question to continue your researchFree to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.
Transcript intelligence
What changed
Relative to the prior quarter, the analysis continues to show raised guidance and strong Skyrizi/Rinvoq momentum, while adding emphasis on tavapadon, PVEK, Temab-A and manufacturing expansion. The risk set remains centered on biosimilars, pricing and aesthetics demand.
Guidance delta
Management raised full-year 2025 guidance, continuing the prior quarter's positive guidance trajectory.
Key takeaways
- Current-quarter analysis points to an EPS and revenue beat, led by Skyrizi and Rinvoq.
- Immunology, neuroscience and aesthetics were identified as key growth areas.
- Management highlighted pipeline progress in tavapadon, PVEK, Temab-A and Rinvoq indications.
- Humira biosimilar erosion remains a pressure, while pricing and reimbursement changes add uncertainty.
Management priorities
- Advance Skyrizi and Rinvoq
- Progress tavapadon, PVEK, Temab-A and Rinvoq indications
- Expand manufacturing capacity and maintain capital investment
- Develop neuroscience, oncology and obesity assets
Follow ABBV with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Wells Fargo | Overweight | Overweight | Maintain | Nov 2, 2026 |
| UBS | Neutral | Neutral | Maintain | Nov 2, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Nov 2, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Nov 2, 2026 |
| Leerink Partners | Outperform | Outperform | Maintain | Nov 2, 2026 |
| Guggenheim | Buy | Buy | Maintain | Nov 2, 2026 |
| Cantor Fitzgerald | Overweight | Overweight | Maintain | Nov 2, 2026 |
| Canaccord Genuity | Buy | Buy | Maintain | Nov 2, 2026 |
| Goldman Sachs | Neutral | Neutral | Maintain | Oct 23, 2026 |
| Barclays | Overweight | Overweight | Maintain | Oct 21, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Oct 8, 2026 |
| Scotiabank | Sector Outperform | Sector Outperform | Maintain | Oct 6, 2026 |
| HSBC | Buy | Buy | Maintain | Sep 10, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Aug 20, 2026 |
| Wolfe Research | Outperform | Peer Perform | Upgrade | Aug 13, 2026 |
| BNP Paribas | Neutral | Neutral | Maintain | Aug 11, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Aug 10, 2026 |
| Berenberg | Buy | Buy | Maintain | Aug 6, 2026 |
| Erste Group | Buy | Hold | Upgrade | Aug 5, 2026 |
| William Blair | Buy | Buy | Maintain | Jul 31, 2026 |
| TD Cowen | Buy | Buy | Maintain | Jul 31, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Jul 15, 2026 |
| BMO Capital | Outperform | Outperform | Maintain | Jul 13, 2026 |
| B of A Securities | Buy | Buy | Maintain | Jul 10, 2026 |
| Freedom Broker | Buy | Buy | Maintain | Feb 17, 2026 |
| Raymond James | Outperform | Outperform | Maintain | Oct 17, 2025 |
| Truist Securities | Buy | Buy | Maintain | Feb 3, 2025 |
| Argus Research | Buy | Hold | Upgrade | Nov 4, 2024 |
| CFRA | Hold | Buy | Downgrade | Mar 29, 2023 |
| SVB Leerink | Market Perform | Underperform | Upgrade | Feb 10, 2023 |
| Atlantic Equities | Neutral | Neutral | Maintain | Feb 10, 2023 |
| Societe Generale | Hold | Buy | Downgrade | Nov 8, 2022 |
| Mizuho | Buy | Buy | Maintain | Feb 4, 2022 |
| Bernstein | Outperform | Outperform | Maintain | Jan 3, 2022 |
| Cowen & Co. | Outperform | Outperform | Maintain | Feb 18, 2020 |
| Citi | Buy | Buy | Maintain | Nov 20, 2019 |
| Piper Jaffray | Overweight | Overweight | Maintain | Sep 4, 2019 |
| Bank of America | Neutral | Buy | Downgrade | Jan 3, 2019 |
| Argus | Buy | Buy | Maintain | Nov 6, 2018 |
| PiperJaffray | Neutral | Overweight | Downgrade | Jun 1, 2018 |
| Credit Suisse | Underperform | Neutral | Downgrade | May 30, 2018 |
| Leerink Swann | Market Perform | Outperform | Downgrade | Jan 29, 2018 |
| Jefferies | Buy | Buy | Maintain | Sep 15, 2017 |
| Deutsche Bank | Hold | Hold | Maintain | Jul 17, 2017 |
Named analyst price targets
Upside is calculated against the persisted current price $286.2. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Piper Sandler | David Amsellem | $349 | $289.2 | +21.9% | Nov 18, 2026 |
| BMO Capital | Analyst unavailable | $315 | $285.67 | +10.1% | Nov 4, 2026 |
| Cantor Fitzgerald | Carter Gould | $325 | $287.17 | +13.6% | Nov 2, 2026 |
| RBC Capital | Trung Huynh | $330 | $288.91 | +15.3% | Nov 2, 2026 |
| Bernstein | Courtney Breen | $275 | $287.99 | -3.9% | Nov 2, 2026 |
| Guggenheim | Vamil Divan | $322 | $294.89 | +12.5% | Nov 2, 2026 |
| Canaccord Genuity | Gary Nachman | $338 | $294.89 | +18.1% | Nov 2, 2026 |
| Wells Fargo | Mohit Bansal | $340 | $294.89 | +18.8% | Nov 2, 2026 |
| UBS | Michael Yee | $295 | $294.89 | +3.1% | Nov 2, 2026 |
| Goldman Sachs | Analyst unavailable | $294 | $284.89 | +2.7% | Oct 23, 2026 |
| Barclays | Analyst unavailable | $325 | $289 | +13.6% | Oct 21, 2026 |
| Cantor Fitzgerald | Carter Gould | $290 | $271.36 | +1.3% | Oct 8, 2026 |
| Morgan Stanley | Analyst unavailable | $310 | $271.89 | +8.3% | Oct 7, 2026 |
| Scotiabank | Louise Chen | $320 | $265.21 | +11.8% | Oct 6, 2026 |
| HSBC | Rajesh Kumar | $315 | $250.98 | +10.1% | Sep 10, 2026 |
| Piper Sandler | Analyst unavailable | $303 | $265.97 | +5.9% | Aug 20, 2026 |
| Wells Fargo | Analyst unavailable | $300 | $249.45 | +4.8% | Aug 17, 2026 |
| Wolfe Research | Alexandria Hammond | $300 | $248.66 | +4.8% | Aug 13, 2026 |
| Guggenheim | Analyst unavailable | $288 | $245.08 | +0.6% | Aug 4, 2026 |
| Morgan Stanley | Analyst unavailable | $296 | $246.26 | +3.4% | Aug 3, 2026 |
| Canaccord Genuity | Gary Nachman | $290 | $250.88 | +1.3% | Aug 3, 2026 |
| Barclays | Analyst unavailable | $300 | $263.48 | +4.8% | Jul 29, 2026 |
| Canaccord Genuity | Analyst unavailable | $282 | $256.15 | -1.5% | Jul 22, 2026 |
| UBS | Analyst unavailable | $260 | $247.05 | -9.2% | Jul 13, 2026 |
| BMO Capital | Analyst unavailable | $300 | $246.69 | +4.8% | Jul 13, 2026 |
| RBC Capital | Trung Huynh | $280 | $246.8 | -2.2% | Jul 10, 2026 |
| Wells Fargo | Analyst unavailable | $295 | $249.91 | +3.1% | Jul 10, 2026 |
| Guggenheim | Analyst unavailable | $261 | $252.61 | -8.8% | Jul 9, 2026 |
| HSBC | Analyst unavailable | $300 | $255.17 | +4.8% | Jul 6, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $265 | $261.07 | -7.4% | Jul 6, 2026 |
| Canaccord Genuity | Analyst unavailable | $273 | $230.06 | -4.6% | Jun 23, 2026 |
| Wells Fargo | Analyst unavailable | $260 | $216.63 | -9.2% | Jun 22, 2026 |
| Evercore ISI | Analyst unavailable | $235 | $212.04 | -17.9% | May 15, 2026 |
| Piper Sandler | Analyst unavailable | $298 | $208.5 | +4.1% | May 14, 2026 |
| Morgan Stanley | Analyst unavailable | $278 | $212.14 | -2.9% | Apr 30, 2026 |
| Piper Sandler | Analyst unavailable | $294 | $200.49 | +2.7% | Apr 23, 2026 |
| Canaccord Genuity | Analyst unavailable | $262 | $203.71 | -8.5% | Apr 20, 2026 |
| Guggenheim | Vamil Divan | $249 | $210.15 | -13.0% | Apr 10, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $240 | $211.59 | -16.1% | Apr 8, 2026 |
| RBC Capital | Trung Huynh | $260 | $228.44 | -9.2% | Feb 24, 2026 |
| Barclays | Analyst unavailable | $275 | $224.35 | -3.9% | Feb 19, 2026 |
| Piper Sandler | Analyst unavailable | $299 | $232.86 | +4.5% | Feb 18, 2026 |
| UBS | Analyst unavailable | $230 | $217.42 | -19.6% | Feb 5, 2026 |
| Evercore ISI | Gavin Clark-Gartner | $228 | $217.02 | -20.3% | Feb 4, 2026 |
| Goldman Sachs | Asad Haider | $223 | $219.77 | -22.1% | Jan 28, 2026 |
| Berenberg Bank | Analyst unavailable | $275 | $214.35 | -3.9% | Jan 20, 2026 |
| BMO Capital | Evan David Seigerman | $258 | $217.74 | -9.9% | Jan 15, 2026 |
| UBS | Analyst unavailable | $240 | $223.93 | -16.1% | Jan 7, 2026 |
| Morgan Stanley | Analyst unavailable | $269 | $222.48 | -6.0% | Dec 12, 2025 |
| HSBC | Analyst unavailable | $265 | $222.99 | -7.4% | Dec 10, 2025 |
| Piper Sandler | David Amsellem | $289 | $213.57 | +1.0% | Nov 5, 2025 |
| Raymond James | Gary Nachman | $256 | $218.04 | -10.6% | Nov 3, 2025 |
| Guggenheim | Analyst unavailable | $242 | $229.57 | -15.4% | Oct 20, 2025 |
| Raymond James | Gary Nachman | $250 | $226.87 | -12.6% | Oct 17, 2025 |
| Piper Sandler | Analyst unavailable | $284 | $230.69 | -0.8% | Oct 10, 2025 |
| Cantor Fitzgerald | Analyst unavailable | $250 | $231.24 | -12.6% | Oct 9, 2025 |
| UBS | Analyst unavailable | $251 | $236.56 | -12.3% | Oct 3, 2025 |
| HSBC | Analyst unavailable | $225 | $244.38 | -21.4% | Oct 2, 2025 |
| Cantor Fitzgerald | Carter Gould | $245 | $218.34 | -14.4% | Sep 15, 2025 |
| Raymond James | Gary Nachman | $220 | $190.14 | -23.1% | Feb 3, 2025 |
| BMO Capital | Evan Seigerman | $215 | $190.14 | -24.9% | Feb 3, 2025 |
| BMO Capital | Evan David Seigerman | $208 | $201.61 | -27.3% | Nov 12, 2024 |
| BMO Capital | Evan David Seigerman | $228 | $201.5 | -20.3% | Oct 31, 2024 |
| Bank of America Securities | Charlie Yang | $210 | $201.5 | -26.6% | Oct 31, 2024 |
| Citigroup | Geoff Meacham | $226 | $201.5 | -21.0% | Oct 31, 2024 |
| Bank of America Securities | Geoff Meacham | $195 | $188.57 | -31.9% | Oct 18, 2024 |
| Bernstein | Courtney Breen | $203 | $190.46 | -29.1% | Oct 17, 2024 |
| Raymond James | Christopher Raymond | $209 | $197.35 | -27.0% | Aug 23, 2024 |
| BMO Capital | Evan Seigerman | $214 | $172.01 | -25.2% | Jul 19, 2024 |
| Raymond James | Christopher Raymond | $190 | $171.36 | -33.6% | Jun 18, 2024 |
| HSBC | Rajesh Kumar | $185 | $162.14 | -35.4% | Jun 5, 2024 |
| Deutsche Bank | James Shin | $175 | $156.96 | -38.9% | May 24, 2024 |
| Cantor Fitzgerald | Louise Chen | $200 | $164.35 | -30.1% | May 17, 2024 |
| BMO Capital | Evan Seigerman | $180 | $158.58 | -37.1% | Apr 29, 2024 |
| Barclays | Carter Gould | $195 | $179.79 | -31.9% | Mar 27, 2024 |
| William Blair | Tim Lugo | $190 | $163.91 | -33.6% | Jan 29, 2024 |
| Raymond James | Christopher Raymond | $170 | $142.03 | -40.6% | Nov 9, 2023 |
| Raymond James | Gary Nachman | $177 | $149.12 | -38.2% | Sep 29, 2023 |
| Guggenheim | Vamil Divan | $171 | $147.01 | -40.3% | May 9, 2023 |
| BMO Capital | Analyst unavailable | $167 | $145.49 | -41.6% | Feb 6, 2023 |
| Morgan Stanley | Analyst unavailable | $182 | $163.44 | -36.4% | Dec 6, 2022 |
| Credit Suisse | Analyst unavailable | $170 | $152.16 | -40.6% | Nov 18, 2022 |
| Leerink Partners | Analyst unavailable | $135 | $142.72 | -52.8% | Sep 30, 2022 |
| Argus Research | Analyst unavailable | $155 | $137.91 | -45.8% | Aug 24, 2022 |
| Barclays | Analyst unavailable | $160 | $143.51 | -44.1% | Aug 1, 2022 |
| Morgan Stanley | Terence Flynn | $191 | $152.15 | -33.3% | Jul 14, 2022 |
| Leerink Partners | David Risinger | $140 | $148.03 | -51.1% | May 24, 2022 |
| Berenberg Bank | Luisa Hector | $135 | $151.01 | -52.8% | May 22, 2022 |
| Morgan Stanley | Terence Flynn | $188 | $147.87 | -34.3% | May 3, 2022 |
| Wells Fargo | Analyst unavailable | $200 | $146.88 | -30.1% | May 2, 2022 |
| BMO Capital | Gary Nachman | $174 | $157.72 | -39.2% | Apr 26, 2022 |
| Barclays | Carter Gould | $174 | $162.31 | -39.2% | Apr 16, 2022 |
| Morgan Stanley | Terence Flynn | $192 | $168.91 | -32.9% | Apr 6, 2022 |
| UBS | Navin Jacob | $147 | $150.56 | -48.6% | Mar 5, 2022 |
| Truist Financial | Robyn Karnauskas | $160 | $144.03 | -44.1% | Feb 21, 2022 |
| Mizuho Securities | Vamil Divan | $166 | $140.65 | -42.0% | Feb 6, 2022 |
| J.P. Morgan | Chris Schott | $180 | $140.73 | -37.1% | Feb 3, 2022 |
| Barclays | Carter Gould | $150 | $140.73 | -47.6% | Feb 3, 2022 |
| Piper Sandler | Christopher Raymond | $160 | $138.62 | -44.1% | Feb 2, 2022 |
| Evercore ISI | Joshua Schimmer | $133 | $137 | -53.5% | Feb 1, 2022 |
| Citigroup | Andrew Baum | $155 | $137.92 | -45.8% | Jan 29, 2022 |
| BMO Capital | Gary Nachman | $153 | $136.78 | -46.5% | Jan 18, 2022 |
| Cowen & Co. | Steve Scala | $150 | $136.78 | -47.6% | Jan 18, 2022 |
| Bernstein | Aaron Gal | $155 | $134.03 | -45.8% | Jan 3, 2022 |
| Wells Fargo | Mohit Bansal | $165 | $120.62 | -42.3% | Dec 8, 2021 |
| Societe Generale | Justin Smith | $172 | $117.66 | -39.9% | Nov 23, 2021 |
| Argus Research | David Toung | $140 | $112.57 | -51.1% | Aug 5, 2021 |
| RBC Capital | Daniel Busby | $135 | $112.9 | -52.8% | Aug 1, 2021 |
| Wolfe Research | Tim Anderson | $127 | $110.91 | -55.6% | May 3, 2021 |
Track every rating change on ABBV the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationAbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism.…
Historical context
All ABBV earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| ASND Ascendis Pharma A/S | FY2026 Q3 · Calendar Q4 2026 | +38.7% | +3.0% | Ascendis Q3 growth broadens the story, while execution risks remain |
| ALC Alcon Inc. | FY2026 Q3 · Calendar Q4 2026 | +2.2% | -2.3% | Alcon holds FY outlook as new launches meet IOL competition |
Latest beats and misses
Who reports nextBeat on EPS
- BJFY2026 Q3 · November 20, 2026+37.3% EPS-5.4% move
- INTUFY2027 Q1 · November 19, 2026+18.3% EPS-6.2% move
- ROSTFY2026 Q3 · November 19, 2026+2.1% EPS-2.8% move
- ESTCFY2027 Q2 · November 19, 2026+16.2% EPS+2.0% move
- KEYSFY2026 Q4 · November 19, 2026+7.1% EPS-1.5% move
- WSMFY2026 Q3 · November 19, 20260.0% EPS-15.2% move
Missed on EPS
- FROFY2026 Q3 · November 20, 2026-11.5% EPS+1.0% move
- NTESFY2026 Q3 · November 19, 2026-12.8% EPS-11.4% move
- FUTUFY2026 Q3 · November 19, 2026-7.8% EPS+4.8% move
- BABAFY2027 Q2 · November 19, 2026-29.2% EPS-1.3% move
- SQMFY2026 Q3 · November 17, 2026-3.0% EPS-5.5% move
- VIKFY2026 Q3 · November 17, 2026-12.6% EPS+4.4% move
Get the ABBV recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:36:15.940040+00:00
- Polygon adjusted daily market bars · 2026-10-01T20:16:11.791151+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-01T20:16:11.788000+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-01. For educational purposes only; not investment advice.